Phase III, Multicenter, Open-label, Randomized Trial of Tarceva® vs Chemotherapy in Patients With Advanced NSCLC With Mutations in the TK Domain of the EGFR (EURTAC)

NCT00446225 Phase 3 COMPLETED Results posted

A Phase III, multicenter, open-label, randomized trial of Erlotinib (Tarceva®) versus chemotherapy in patients with advanced NSCLC with mutations in the Tyrosine Kinase (TK) domain of the EGFR.

Details

Lead sponsor	Spanish Lung Cancer Group
Phase	Phase 3
Status	COMPLETED
Enrolment	174
Start date	2007-02-15
Completion	2012-12

Conditions

• Non-Small Cell Lung Cancer

Interventions

• Erlotinib
• Carboplatin
• Gemcitabin
• Docetaxel
• Cisplatin

Primary outcomes

• Progression Free-survival — From the date of randomization to the date of last follow up, assessed up to 24 months
  The time from enrollment in the study to tumor progression or death from any cause (whichever occurs first)

Countries

France, Italy, Spain